These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28864139)

  • 1. Optimizing Antithymocyte Globulin Dosing for Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Based on Recipient Absolute Lymphocyte Count.
    Kennedy VE; Chen H; Savani BN; Greer J; Kassim AA; Engelhardt BG; Goodman S; Sengsayadeth S; Chinratanalab W; Jagasia M
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):150-155. PubMed ID: 28864139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does Lymphocyte Count Impact Dosing of Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplantation?
    Heelan F; Mallick R; Bryant A; Radhwi O; Atkins H; Huebsch L; Bredeson C; Allan D; Kekre N
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1298-1302. PubMed ID: 32165325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preconditioning Absolute Lymphocyte Count and Transplantation Outcomes in Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Reduced-Intensity Conditioning and Antithymocyte Globulin Treatment.
    Woo GU; Hong J; Kim H; Byun JM; Koh Y; Shin DY; Kim I; Yoon SS
    Biol Blood Marrow Transplant; 2020 Oct; 26(10):1855-1860. PubMed ID: 32561338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes with low dose anti-thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation.
    Chalchal H; Dhir V; Masurekar A; Atkins H; Bredeson C; Kennah M; Kekre N; Allan D; Vasudevan Nampoothiri R
    Eur J Haematol; 2024 Oct; 113(4):543-549. PubMed ID: 38979885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-Based Antithymocyte Globulin in αβhaplo-Hematopoietic Stem Cell Transplantation Facilitates Engraftment, Expedites T Cell Recovery, and Mitigates the Risk of Acute Graft-versus-Host Disease.
    Barbarito G; Hiroshima L; Oppizzi L; Saini G; Kristovich K; Klein O; Hosszu K; Boehlke K; Gupta A; Mcavoy D; Shyr D; Boelens JJ; Bertaina A
    Transplant Cell Ther; 2024 Aug; 30(8):810.e1-810.e16. PubMed ID: 38768907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antithymocyte globulin for GVHD prophylaxis in allogeneic hematopoietic stem cell transplantation].
    Shiratori S
    Rinsho Ketsueki; 2021; 62(8):1265-1274. PubMed ID: 34497215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34
    Scordo M; Bhatt V; Hilden P; Smith M; Thoren K; Cho C; Shah GL; Maloy MA; Papadopoulos EB; Jakubowski AA; Avecilla ST; O'Reilly RJ; Castro-Malaspina H; Tamari R; Shaffer BC; Boelens JJ; Perales MA; Giralt SA
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1526-1535. PubMed ID: 30831208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High lymphocyte counts before antithymocyte globulin administration predict acute graft-versus-host disease.
    Shiratori S; Ohigashi H; Ara T; Yasumoto A; Goto H; Nakagawa M; Sugita J; Onozawa M; Kahata K; Endo T; Hashimoto D; Teshima T
    Ann Hematol; 2021 May; 100(5):1321-1328. PubMed ID: 33215225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
    Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
    Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
    Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation.
    Devillier R; Labopin M; Chevallier P; Ledoux MP; Socié G; Huynh A; Bourhis JH; Cahn JY; Roth-Guepin G; Mufti G; Desmier D; Michallet M; Fegueux N; Ciceri F; Baron F; Blaise D; Nagler A; Mohty M
    Bone Marrow Transplant; 2018 Apr; 53(4):431-437. PubMed ID: 29330391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.
    Shah AJ; Kapoor N; Crooks GM; Weinberg KI; Azim HA; Killen R; Kuo L; Rushing T; Kohn DB; Parkman R
    Biol Blood Marrow Transplant; 2007 May; 13(5):584-93. PubMed ID: 17448918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different
    Sheth V; Kennedy V; de Lavallade H; Mclornan D; Potter V; Engelhardt BG; Savani B; Chinratanalab W; Goodman S; Greer J; Kassim A; York S; Kenyon M; Gandhi S; Kulasekararaj A; Marsh J; Mufti G; Pagliuca A; Jagasia M; Raj K
    Front Oncol; 2019; 9():623. PubMed ID: 31355140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of antithymocyte globulin on HLA-mismatched unrelated transplantation.
    Kawamura K
    Int J Hematol; 2019 Jul; 110(1):22-29. PubMed ID: 30680666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors.
    Shiratori S; Sugita J; Fuji S; Aoki J; Sawa M; Ozawa Y; Hashimoto D; Matsuoka KI; Imada K; Doki N; Ashida T; Ueda Y; Tanaka M; Sawayama Y; Ichinohe T; Terakura S; Morishima S; Atsuta Y; Fukuda T; Teshima T
    Bone Marrow Transplant; 2021 Sep; 56(9):2231-2240. PubMed ID: 33963304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine Release Syndrome during Antithymocyte Globulin/Anti-T Lymphocyte Globulin Serotherapy for Graft-versus-Host Disease Prophylaxis before Allogeneic Hematopoietic Stem Cell Transplantation: Incidence and Early Clinical Impact According to American Society of Transplantation and Cellular Therapy Grading Criteria.
    Knaus HA; Rottner T; Baumann CK; Cserna J; Mitterbauer M; Schulenburg A; Rabitsch W; Wohlfarth P
    Transplant Cell Ther; 2022 May; 28(5):260.e1-260.e9. PubMed ID: 35217212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.